Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: Interaction with the effects of adenosine A2A antagonism

Lyndsey E. Collins-Praino, Nicholas E. Paul, Felicia Ledgard, Samantha J. Podurgiel, Rotem Kovner, Younis Baqi, Christa E. Müller, Patrick B. Senatus, John D. Salamone

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Deep brain stimulation (DBS) of the subthalamic nucleus is increasingly being employed as a treatment for parkinsonian symptoms, including tremor. The present studies used tremulous jaw movements, a pharmacological model of tremor in rodents, to investigate the tremorolytic effects of subthalamic DBS in rats. Subthalamic DBS reduced the tremulous jaw movements induced by the dopamine D2 family antagonist pimozide and the D1 family antagonist ecopipam, as well as the cholinomimetics pilocarpine and galantamine. The ability of DBS to suppress tremulous jaw movements was dependent on the neuroanatomical locus being stimulated (subthalamic nucleus vs. a striatal control site), as well as the frequency and intensity of stimulation used. Importantly, administration of the adenosine A2A receptor antagonist MSX-3 reduced the frequency and intensity parameters needed to attenuate tremulous jaw movements. These results have implications for the clinical use of DBS, and future studies should determine whether adenosine A2A antagonism could be used to enhance the tremorolytic efficacy of subthalamic DBS at low frequencies and intensities in human patients.

Original languageEnglish
Pages (from-to)2183-2191
Number of pages9
JournalEuropean Journal of Neuroscience
Volume38
Issue number1
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Subthalamic Nucleus
Deep Brain Stimulation
Parkinsonian Disorders
Tremor
Adenosine
Pharmacology
Jaw
Adenosine A2 Receptor Antagonists
Galantamine
Pimozide
Corpus Striatum
Pilocarpine
Aptitude
Cholinergic Agents
Rodentia

Keywords

  • acetylcholine
  • dopamine
  • muscarinic
  • Parkinson's disease
  • tremulous jaw movements

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism : Interaction with the effects of adenosine A2A antagonism. / Collins-Praino, Lyndsey E.; Paul, Nicholas E.; Ledgard, Felicia; Podurgiel, Samantha J.; Kovner, Rotem; Baqi, Younis; Müller, Christa E.; Senatus, Patrick B.; Salamone, John D.

In: European Journal of Neuroscience, Vol. 38, No. 1, 07.2013, p. 2183-2191.

Research output: Contribution to journalArticle

Collins-Praino, Lyndsey E. ; Paul, Nicholas E. ; Ledgard, Felicia ; Podurgiel, Samantha J. ; Kovner, Rotem ; Baqi, Younis ; Müller, Christa E. ; Senatus, Patrick B. ; Salamone, John D. / Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism : Interaction with the effects of adenosine A2A antagonism. In: European Journal of Neuroscience. 2013 ; Vol. 38, No. 1. pp. 2183-2191.
@article{3c61e456dce34f39bce17054de4c2d5e,
title = "Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: Interaction with the effects of adenosine A2A antagonism",
abstract = "Deep brain stimulation (DBS) of the subthalamic nucleus is increasingly being employed as a treatment for parkinsonian symptoms, including tremor. The present studies used tremulous jaw movements, a pharmacological model of tremor in rodents, to investigate the tremorolytic effects of subthalamic DBS in rats. Subthalamic DBS reduced the tremulous jaw movements induced by the dopamine D2 family antagonist pimozide and the D1 family antagonist ecopipam, as well as the cholinomimetics pilocarpine and galantamine. The ability of DBS to suppress tremulous jaw movements was dependent on the neuroanatomical locus being stimulated (subthalamic nucleus vs. a striatal control site), as well as the frequency and intensity of stimulation used. Importantly, administration of the adenosine A2A receptor antagonist MSX-3 reduced the frequency and intensity parameters needed to attenuate tremulous jaw movements. These results have implications for the clinical use of DBS, and future studies should determine whether adenosine A2A antagonism could be used to enhance the tremorolytic efficacy of subthalamic DBS at low frequencies and intensities in human patients.",
keywords = "acetylcholine, dopamine, muscarinic, Parkinson's disease, tremulous jaw movements",
author = "Collins-Praino, {Lyndsey E.} and Paul, {Nicholas E.} and Felicia Ledgard and Podurgiel, {Samantha J.} and Rotem Kovner and Younis Baqi and M{\"u}ller, {Christa E.} and Senatus, {Patrick B.} and Salamone, {John D.}",
year = "2013",
month = "7",
doi = "10.1111/ejn.12212",
language = "English",
volume = "38",
pages = "2183--2191",
journal = "European Journal of Neuroscience",
issn = "0953-816X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism

T2 - Interaction with the effects of adenosine A2A antagonism

AU - Collins-Praino, Lyndsey E.

AU - Paul, Nicholas E.

AU - Ledgard, Felicia

AU - Podurgiel, Samantha J.

AU - Kovner, Rotem

AU - Baqi, Younis

AU - Müller, Christa E.

AU - Senatus, Patrick B.

AU - Salamone, John D.

PY - 2013/7

Y1 - 2013/7

N2 - Deep brain stimulation (DBS) of the subthalamic nucleus is increasingly being employed as a treatment for parkinsonian symptoms, including tremor. The present studies used tremulous jaw movements, a pharmacological model of tremor in rodents, to investigate the tremorolytic effects of subthalamic DBS in rats. Subthalamic DBS reduced the tremulous jaw movements induced by the dopamine D2 family antagonist pimozide and the D1 family antagonist ecopipam, as well as the cholinomimetics pilocarpine and galantamine. The ability of DBS to suppress tremulous jaw movements was dependent on the neuroanatomical locus being stimulated (subthalamic nucleus vs. a striatal control site), as well as the frequency and intensity of stimulation used. Importantly, administration of the adenosine A2A receptor antagonist MSX-3 reduced the frequency and intensity parameters needed to attenuate tremulous jaw movements. These results have implications for the clinical use of DBS, and future studies should determine whether adenosine A2A antagonism could be used to enhance the tremorolytic efficacy of subthalamic DBS at low frequencies and intensities in human patients.

AB - Deep brain stimulation (DBS) of the subthalamic nucleus is increasingly being employed as a treatment for parkinsonian symptoms, including tremor. The present studies used tremulous jaw movements, a pharmacological model of tremor in rodents, to investigate the tremorolytic effects of subthalamic DBS in rats. Subthalamic DBS reduced the tremulous jaw movements induced by the dopamine D2 family antagonist pimozide and the D1 family antagonist ecopipam, as well as the cholinomimetics pilocarpine and galantamine. The ability of DBS to suppress tremulous jaw movements was dependent on the neuroanatomical locus being stimulated (subthalamic nucleus vs. a striatal control site), as well as the frequency and intensity of stimulation used. Importantly, administration of the adenosine A2A receptor antagonist MSX-3 reduced the frequency and intensity parameters needed to attenuate tremulous jaw movements. These results have implications for the clinical use of DBS, and future studies should determine whether adenosine A2A antagonism could be used to enhance the tremorolytic efficacy of subthalamic DBS at low frequencies and intensities in human patients.

KW - acetylcholine

KW - dopamine

KW - muscarinic

KW - Parkinson's disease

KW - tremulous jaw movements

UR - http://www.scopus.com/inward/record.url?scp=84879844751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879844751&partnerID=8YFLogxK

U2 - 10.1111/ejn.12212

DO - 10.1111/ejn.12212

M3 - Article

C2 - 23600953

AN - SCOPUS:84879844751

VL - 38

SP - 2183

EP - 2191

JO - European Journal of Neuroscience

JF - European Journal of Neuroscience

SN - 0953-816X

IS - 1

ER -